These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10195233)

  • 21. Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy.
    Joshi SR; Butala N; Patwardhan MR; Daver NG; Kelkar D
    J Assoc Physicians India; 2004 Jul; 52():597-8. PubMed ID: 15645995
    [No Abstract]   [Full Text] [Related]  

  • 22. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
    Rodriguez SK; Sarr AD; Olorunnipa O; Popper SJ; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Infect Dis; 2006 Sep; 194(6):760-3. PubMed ID: 16941341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
    Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
    J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
    Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
    Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trial suggests vaccines could aid HIV therapy.
    Check E
    Nature; 2003 Apr; 422(6933):650. PubMed ID: 12700722
    [No Abstract]   [Full Text] [Related]  

  • 27. AIDS. Escape from the immune system.
    Walker BD; Goulder PJ
    Nature; 2000 Sep; 407(6802):313-4. PubMed ID: 11014174
    [No Abstract]   [Full Text] [Related]  

  • 28. Hydroxyurea for HIV?
    Treat Rev; 1998; (No 28):10-2. PubMed ID: 11365419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.
    Haslett PA; Nixon DF; Shen Z; Larsson M; Cox WI; Manandhar R; Donahoe SM; Kaplan G
    J Infect Dis; 2000 Apr; 181(4):1264-72. PubMed ID: 10751137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application.
    Caputo A; Brocca-Cofano E; Castaldello A; De Michele R; Altavilla G; Marchisio M; Gavioli R; Rolen U; Chiarantini L; Cerasi A; Dominici S; Magnani M; Cafaro A; Sparnacci K; Laus M; Tondelli L; Ensoli B
    Vaccine; 2004 Jul; 22(21-22):2910-24. PubMed ID: 15246628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
    Bråve A; Hinkula J; Cafaro A; Eriksson LE; Srivastava IK; Magnani M; Ensoli B; Barnett SW; Wahren B; Rollman E
    Vaccine; 2007 Sep; 25(39-40):6882-90. PubMed ID: 17707956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interrupting HAART; Hydroxyurea; five+ drug therapy - report from the RIGHT Conference.
    Levin J
    AIDS Treat News; 1999 May; (No 318):3-4. PubMed ID: 11366456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HIV-1 Tat transactivator protein: a therapeutic target?
    Fulcher AJ; Jans DA
    IUBMB Life; 2003 Dec; 55(12):669-80. PubMed ID: 14769003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Debunking hCG.
    Sairam MR; Antakly T
    Nat Biotechnol; 1997 Nov; 15(12):1228. PubMed ID: 9359097
    [No Abstract]   [Full Text] [Related]  

  • 36. Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(2):1-2. PubMed ID: 11365124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment -- study results.
    Treat Rev; 1996 Dec; (No 23):4-11. PubMed ID: 11364282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.
    Gallo RC
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8324-6. PubMed ID: 10411869
    [No Abstract]   [Full Text] [Related]  

  • 39. The world of HIV and disease, and some new approaches to block it.
    Gallo R
    Bull Mem Acad R Med Belg; 1998; 153(7-9):339-42. PubMed ID: 10100397
    [No Abstract]   [Full Text] [Related]  

  • 40. Perspectives in HIV pathogenesis, treatment, and prevention.
    Rappaport J
    Biomed Pharmacother; 2003 Jan; 57(1):1-3. PubMed ID: 12642030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.